These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
727 related articles for article (PubMed ID: 34461944)
21. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment. Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832 [TBL] [Abstract][Full Text] [Related]
22. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246 [TBL] [Abstract][Full Text] [Related]
23. YAP/STAT3 inhibited CD8 Wang C; Shen N; Guo Q; Tan X; He S Cancer Med; 2023 Aug; 12(15):16295-16309. PubMed ID: 37329188 [TBL] [Abstract][Full Text] [Related]
24. Tramadol suppresses growth of orthotopic liver tumors via promoting M1 macrophage polarization in the tumor microenvironment. Wang L; Guo W; Guan H; Yan N; Cai X; Zhu L Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4205-4218. PubMed ID: 38041778 [TBL] [Abstract][Full Text] [Related]
25. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4 Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845 [TBL] [Abstract][Full Text] [Related]
26. XIAOPI Formula Inhibits Breast Cancer Stem Cells Wang S; Liu X; Huang R; Zheng Y; Wang N; Yang B; Situ H; Lin Y; Wang Z Front Pharmacol; 2019; 10():1371. PubMed ID: 31803057 [TBL] [Abstract][Full Text] [Related]
27. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304 [TBL] [Abstract][Full Text] [Related]
29. PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination. Franzolin G; Brundu S; Cojocaru CF; Curatolo A; Ponzo M; Mastrantonio R; Mihara E; Kumanogoh A; Suga H; Takagi J; Tamagnone L; Giraudo E Cancer Immunol Res; 2024 Sep; 12(9):1286-1301. PubMed ID: 38874583 [TBL] [Abstract][Full Text] [Related]
30. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
31. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways. Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082 [TBL] [Abstract][Full Text] [Related]
32. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression. Stenström J; Hedenfalk I; Hagerling C Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289 [TBL] [Abstract][Full Text] [Related]
33. Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages. Ahirwar DK; Charan M; Mishra S; Verma AK; Shilo K; Ramaswamy B; Ganju RK Cancer Res; 2021 Oct; 81(20):5255-5267. PubMed ID: 34400395 [TBL] [Abstract][Full Text] [Related]
34. Lidocaine combined with general anesthetics impedes metastasis of breast cancer cells via inhibition of TGF-β/Smad-mediated EMT signaling by reprogramming tumor-associated macrophages. Seok Han B; Ko S; Seok Park M; Ji Lee Y; Eun Kim S; Lee P; Jin Cho Y; Gyeol Go H; Kwak S; Park E; Lim A; Lee S; Yoo S; Kim H; Hee Jung K; Hong SS Int Immunopharmacol; 2024 Dec; 142(Pt B):113207. PubMed ID: 39312860 [TBL] [Abstract][Full Text] [Related]
35. Curcumin regulates the differentiation of naïve CD4+T cells and activates IL-10 immune modulation against acute lung injury in mice. Chai YS; Chen YQ; Lin SH; Xie K; Wang CJ; Yang YZ; Xu F Biomed Pharmacother; 2020 May; 125():109946. PubMed ID: 32004976 [TBL] [Abstract][Full Text] [Related]
36. Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice. Li X; Meng Y; Plotnikoff NP; Youkilis G; Griffin N; Wang E; Lu C; Shan F Cancer Biol Ther; 2015; 16(3):450-9. PubMed ID: 25701137 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Ye T; Wei X; Yin T; Xia Y; Li D; Shao B; Song X; He S; Luo M; Gao X; He Z; Luo C; Xiong Y; Wang N; Zeng J; Zhao L; Shen G; Xie Y; Yu L; Wei Y Breast Cancer Res Treat; 2014 Feb; 143(3):435-46. PubMed ID: 24398778 [TBL] [Abstract][Full Text] [Related]
38. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. Jang JY; Lee JK; Jeon YK; Kim CW BMC Cancer; 2013 Sep; 13():421. PubMed ID: 24044575 [TBL] [Abstract][Full Text] [Related]
39. XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy. Wang N; Yang B; Muhetaer G; Wang S; Zheng Y; Lu J; Li M; Zhang F; Situ H; Lin Y; Wang Z Biomed Pharmacother; 2019 Dec; 120():109519. PubMed ID: 31629951 [TBL] [Abstract][Full Text] [Related]
40. Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-β receptor. Guo J; Chen T; Ma Z; Qiao C; Yuan F; Guo X; Liu J; Shen Y; Yu L; Xiang A Int Immunopharmacol; 2020 Nov; 88():106831. PubMed ID: 32853925 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]